Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Lawrence K. Oliver"'
Autor:
Stefan K.G. Grebe, Maureen Luby, Spencer A. Brown, Avron H. Lipschitz, Greene Shepherd, Lawrence K. Oliver, Rod J. Rohrich, Jeffrey M. Kenkel, Evan S. Sorokin
Publikováno v:
Plastic and Reconstructive Surgery. 114:756-763
Patients are routinely exposed to high-dose epinephrine infiltration during large-volume liposuction. Because of the serious cardiovascular side-effect profile of catecholamine overdose, the authors examined the safety of larger-volume liposuction by
Publikováno v:
Sleep. 25:733-736
Study Objectives: Hypocretin (orexin) deficiency (< 40 pg/ml) is highly associated with narcolepsy with cataplexy (89.5%) and more specifically with patients with cataplexy who are HLA DQB1*0602 positive (95.7%). The relationship between hypocretin-1
Autor:
Zelalem Temesgen, Thomas P. Moyer, Lynn L. Estes, Lawrence K. Oliver, Alan J. Wright, Robert J. Enger, Joel R. Charlson
Publikováno v:
Clinical Chemistry. 45:1465-1476
Background: Antiretroviral therapy for HIV-1 infection has become increasingly complex. The availability of new and potent drugs and progress in understanding the pathogenesis of HIV-1 infection have led to the establishment of new treatment paradigm
Autor:
Thomas P. Moyer, Lawrence K. Oliver
Publikováno v:
Clinical Chemistry. 44:433-436
Well-founded pharmacokinetic information is one of the cornerstones of a New Drug Application (NDA) to the Food and Drug Administration (FDA) required to introduce a new drug or a generic equivalent (ANDA) to the marketplace. The service that laborat
Publikováno v:
Sleep Medicine. 3:521-523
Narcolepsy secondary to other neurologic processes has been recently associated with hypocretin (orexin) deficiency. We present a patient who developed a narcoleptic-like sleep disorder after receiving treatment for a choroid plexus carcinoma of the
Autor:
Allan S. Jaffe, Don Heser, Heidi Callanan, Nikolay Voskoboev, Joseph P. McConnell, Lawrence K. Oliver, Shannon Hodel-Hanson
Publikováno v:
Clinical biochemistry. 44(14-15)
Objectives Lp-PLA2 is a biomarker with promise for predicting cardiac risk. The lack of reproducible results has limited its use. In evaluating a new reagent kit, we investigated conditions for optimal reproducibility. Methods The Auto-PLAC reagents
Autor:
Joseph R. Berger, Delia Bethell, Peter G. Blain, John C.M. Brust, D. Brandon Burtis, Mary Capelli-Schellpfeffer, Sarah A. Carr, Jane W. Chan, Pratap Chand, Sundeep Dhillon, Michael R. Dobbs, Peter D. Donofrio, Thierry Philippe Jacques Duprez, Tracy J. Eicher, Alberto J. Espay, Jeremy Farrar, Dominic B. Fee, Larry W. Figgs, Jordan A. Firestone, Arthur D. Forman, Brent Furbee, Ray F. Garman, Des Gorman, Sidney M. Gospe, David G. Greer, Patrick M. Grogan, Philippe Hantson, Tran Tinh Hien, Michael Hoffmann, Christopher P. Holstege, Amber N. Hood, Maria K. Houtchens, J. Stephen Huff, Col. (S) Michael S. Jaffee, David A. Jett, Gregory A. Jicha, Bryan S. Judge, Jonathan S. Katz, Kara A. Kennedy, Hani A. Kushlaf, David Lawrence, Victor A. Levin, Elizabeth Lienemann, Steven B. Lippmann, Nancy McLinskey, Christina A. Meyers, Puneet Narang, Jonathan Newmark, John P. Ney, Lawrence K. Oliver, Peter J. Osterbauer, Sumit Parikh, L. Cameron Pimperl, Terri L. Postma, T. Scott Prince, Leon Prockop, Jason R. Richardson, Daniel E. Rusyniak, Melody Ryan, Redda Tekle Haimamot, Brett J. Theeler, Asit K. Tripathy, Anand G. Vaishnav, David R. Wallace, Michael R. Watters, Brandon Wills
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0be2f5a31315799a69ae119de8f61264
https://doi.org/10.1016/b978-032305260-3.50003-4
https://doi.org/10.1016/b978-032305260-3.50003-4
Autor:
Errol B. De Souza, Rudolf Hoehn-Saric, Daniel R. McLeod, Wesley D. Zimmerli, Lawrence K. Oliver
Publikováno v:
Biological Psychiatry. 28:849-861
The correspondence between changes in physiological activity and somatic symptom reports was assessed in generalized anxiety disorder patients treated with alprazolam or imipramine. After 6 weeks, the two medications produced comparable reductions in
Autor:
Ronald A. Fleming, Robert L. Capizzi, Gary L. Rosner, Raymond B. Weiss, George A. Omura, Bruce A. Peterson, Robert J. Mayer, Clara D. Bloomfield, Lawrence K. Oliver, David A. Van Echo, Stephen J. Smith, Richard L. Schilsky, Richard T. Silver, Charles A. Schiffer
Publikováno v:
Cancer chemotherapy and pharmacology. 36(5)
The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviati